KHRN.V - Khiron Life Sciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.5700
-0.0100 (-1.72%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.5800
Open0.5700
Bid0.5700 x 0
Ask0.5700 x 0
Day's Range0.5500 - 0.5800
52 Week Range0.3000 - 3.7500
Volume102,673
Avg. Volume521,409
Market Cap66.469M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3950
Earnings DateMay 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.67
  • CNW Group

    Khiron to Educate Physicians on Medical Cannabis Online with Leading Latin American University

    Agreement with Tecnologico de Monterrey , a leading Latin American university (Third Ranked in Latin America ) in Mexico brings Khiron´s online education program to reach 1,500 physicians, healthcare practitioners ...

  • CNW Group

    Khiron Meets Essential Patient Needs with Launch of Teleconsultation Services in Colombia

    Khiron Meets Essential Patient Needs with Launch of Teleconsultation Services in Colombia

  • CNW Group

    IIROC Trading Resumption - KHRN

    IIROC Trading Resumption - KHRN

  • CNW Group

    Khiron Readies for First Medical Sales in Colombia and Provides Corporate Update

    Khiron Readies for First Medical Sales in Colombia and Provides Corporate Update

  • CNW Group

    IIROC Trading Halt - KHRN

    VANCOUVER , March 19, 2020 /CNW/ - The following issues have been halted by IIROC: Company: Khiron Life Sciences Corp. TSX-Venture Symbol: KHRN (All Issues) Reason: At the Request of the Company Pending ...

  • Did Changing Sentiment Drive Khiron Life Sciences's (CVE:KHRN) Share Price Down A Painful 87%?
    Simply Wall St.

    Did Changing Sentiment Drive Khiron Life Sciences's (CVE:KHRN) Share Price Down A Painful 87%?

    As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...

  • CNW Group

    Khiron Poised to Enter Medical Cannabis Market in Peru

    Signed a 2-year exclusive agreement to manufacture and distribute Khiron-branded medical cannabis products in Lima , Peru´s largest city with 8.6 million inhabitants With 10 locations in Lima , Farmacia ...

  • ACCESSWIRE

    Khiron President Chris Naprawa To Present at 2020 LD Micro Virtual Conference

    TORONTO, ON / ACCESSWIRE / March 3, 2020 / Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced today that the Company will be presenting at the third annual LD Micro Virtual Conference on Tuesday March 3rd at 1:40pm PST/4:40pm EST. Khiron President Chris Naprawa will present and take questions from investors.

  • CNW Group

    Khiron is First Company Authorized to Extract High THC Medical Cannabis in Colombia

    Further to cultivation quotas announced on February 26, 2020, this authorization by the Colombian Technical Quotas Authority ("TQG") allows the Company to now produce oils for sale both domestically and abroad. Export quotas allow for the manufacture of whole plant extract for international purposes to countries such as Peru, Uruguay and Brazil, thereby accessing to a medical cannabis market of $1.4 Billion. Domestic quotas represent a further milestone in the Company's stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy.

  • CNW Group

    Khiron Receives Approval of Normal Course Issuer Bid

    TORONTO , Feb. 27, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), a vertically integrated cannabis leader with core operations in Latin America , is pleased to announce that, further to its February 11, 2020 press release, the Company has received final approval from the TSX Venture Exchange (the "TSXV") for a normal course issuer bid to repurchase, for cancellation, up to 5,830,615 common shares of the Company ("Shares"), representing approximately 5% of the Company's presently issued and outstanding Shares (the "NCIB").

  • CNW Group

    Khiron Granted Approval to Cultivate 9.3 Tons of THC Cannabis, Representing 17% of the Total Allocated Quota for Colombia in 2020

    Colombia was granted a total production quota of 56.2 tons of medical cannabis for 2020 by the International Narcotics Control Board ("INCB"), the entity responsible for the implementation of the United Nations drug conventions. This represents 21.9% of the world´s legal global supply of high THC medical cannabis. The Company will begin cultivation activities immediately in its existing state-of-the-art facility near Ibague, Colombia , with its already-registered strains.

  • CNW Group

    Khiron Announces Plans to Expand Kuida® Distribution to Spain

    Company prepares to bring Kuida CBD brand to Spain with receipt of "no objection" letter from TSXV, subject to complying with all regulatory requirements in Spain As previously announced, Khiron ...

  • CNW Group

    Khiron to Participate in 3rd Annual Gravitas Growth Conference in Vancouver, BC

    TORONTO, Feb. 14, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce it will be participating in the 3rd Annual Gravitas Growth Conference taking place February 20th, 2020 at the Fairmont Pacific Rim Hotel in Vancouver, BC. Mr. Naprawa will also host individual investor meetings on February 20th at this year's Gravitas Growth Conference, which will feature approximately 20 companies and will be attended by over 250 individuals.

  • CNW Group

    Khiron Announces Normal Course Issuer Bid

    TORONTO , Feb. 11, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF) (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , announces today its intention to commence a normal course issuer bid through the facilities of the TSX Venture Exchange (the "TSXV") to repurchase, for cancellation, up to 5,830,615 common shares of the Company ("Shares"), representing approximately 5% of the Company's presently issued and outstanding Shares (the "NCIB").